Krantz A, Spencer R W, Tam T F, Liak T J, Copp L J, Thomas E M, Rafferty S P
Syntex Research, Canada, Mississauga, Ontario.
J Med Chem. 1990 Feb;33(2):464-79. doi: 10.1021/jm00164a002.
4H-3,1-Benzoxazin-4-ones are alternate substrate inhibitors of the serine proteinase human leukocyte elastase (HL elastase) and form acyl enzyme intermediates during enzyme catalysis. We have synthesized a large variety of benzoxazinones using specific methods that have been adapted to achieve the pattern of ring substitution dictated by theoretical considerations. The results of the inhibition of HL elastase by 175 benzoxazinones are reported herein with reference to hydrophobicity constants D, alkaline hydrolysis rates kOH-, inhibition constants Ki, and their component acylation and deacylation rate constants, kon and koff, respectively. The ranges for the compounds are considerable; alkaline hydrolysis rates and kon span 6, koff covers 5, and ki spans 8 orders of magnitude. Multiple regression on this large data set has been used to isolate the contributions of electronic and steric effects, as well as other factors specific to compound stability and elastase inhibition. Essentially, a simple electronic parameter is sufficient to account for almost all the variance in the alkaline hydrolysis data, indicating that electronic factors are the major determinants of this type of benzoxazinone reactivity. Factors that significantly enhance the potency of benzoxazinones I are R5 alkyl groups and electron withdrawal by R2. Bulk in R7 and R8 and compound hydrophobicity are not significant, but substitution in R6 is highly unfavorable as are substituents linked via carbon to C2. The physiochemical factors that underlie these trends in Ki are further analyzed in terms of equations that describe kon and koff. A conclusion that emerges is that chemically stable, potent benzoxazinone inhibitors of HL elastase with inhibition constants in the nanomolar range can be designed with (1) R5 alkyl groups to inhibit enzyme-catalyzed deacylation, (2) small alkyl substituents linked via heteroatoms to C2 to enhance acylation and limit deacylation rates, and (3) strongly electron-donating groups at C7 to stabilize the oxazinone ring to nucleophilic attack. Thus, 2-(isopropylamino)-5-n-propyl-7-(dimethylamino)benzoxazinone 95 has kOH = 0.01 M-1 s-1, which extrapolates to a half-life at pH 7.4 of over 8.5 years, and 2-ethoxy-5-ethylbenzoxazinone 38 has Ki = 42 pM.
4H - 3,1 - 苯并恶嗪 - 4 - 酮是丝氨酸蛋白酶人白细胞弹性蛋白酶(HL弹性蛋白酶)的替代底物抑制剂,在酶催化过程中形成酰基酶中间体。我们使用特定方法合成了多种苯并恶嗪酮,这些方法经过调整以实现理论考虑所规定的环取代模式。本文报道了175种苯并恶嗪酮对HL弹性蛋白酶的抑制结果,涉及疏水性常数D、碱性水解速率kOH - 、抑制常数Ki以及它们各自的酰化和脱酰化速率常数kon和koff。这些化合物的范围相当大;碱性水解速率和kon跨越6个数量级,koff涵盖5个数量级,Ki跨越8个数量级。对这个大数据集进行多元回归,以分离电子和空间效应以及其他与化合物稳定性和弹性蛋白酶抑制相关的特定因素的贡献。基本上,一个简单的电子参数足以解释碱性水解数据中几乎所有的变化,表明电子因素是这类苯并恶嗪酮反应性的主要决定因素。能显著提高苯并恶嗪酮I效力的因素是R5烷基和R2的吸电子作用。R7和R8中的体积和化合物疏水性并不显著,但R6中的取代非常不利,通过碳与C2相连的取代基也是如此。根据描述kon和koff的方程,进一步分析了这些Ki趋势背后的物理化学因素。得出的结论是,可以设计出化学稳定、效力强且抑制常数在纳摩尔范围内的HL弹性蛋白酶苯并恶嗪酮抑制剂,方法是:(1)使用R5烷基抑制酶催化的脱酰化;(2)通过杂原子与C2相连的小烷基取代基增强酰化并限制脱酰化速率;(3)在C7处有强给电子基团以稳定恶嗪酮环免受亲核攻击。因此,2 - (异丙基氨基) - 5 - 正丙基 - 7 - (二甲氨基)苯并恶嗪酮95的kOH = 0.01 M - 1 s - 1,外推至pH 7.4时的半衰期超过8.5年,2 - 乙氧基 - 5 - 乙基苯并恶嗪酮38的Ki = 42 pM。